Search Results for keywords:"Drug Enforcement Administration"

Cedarburg Pharmaceuticals has applied to the Drug Enforcement Administration (DEA) to become a registered bulk manufacturer of controlled substances. The company plans to produce synthetic Tetrahydrocannabinols (THC) as an active pharmaceutical ingredient for distribution. Interested parties, including current manufacturers or applicants, can submit comments or request a hearing regarding this application by March 15, 2021. The DEA is handling correspondence related to this application.

The Drug Enforcement Administration (DEA) has revoked the DEA registration of Dr. Victor Augusto Silva from Tampa, Florida, due to his failure to comply with federal and state laws regarding controlled substances. The DEA found that Dr. Silva allowed an unauthorized individual to use his registration to issue prescriptions for controlled substances, which is against the law. As Dr. Silva did not adequately respond to the charges or demonstrate he can be trusted with prescribing controlled substances, the DEA determined his continued registration would not serve the public interest. As a result, his registration was revoked, and any pending applications for registration in Florida were denied.

Noramco has submitted an application to the Drug Enforcement Administration (DEA) to become a registered bulk manufacturer of controlled substances. The company specifically plans to produce active pharmaceutical ingredients, including synthetic marihuana and tetrahydrocannabinols. Individuals or organizations can submit comments or objections to this application by March 25, 2025, through the Federal eRulemaking Portal. The announcement provides further details about the application and the procedures for submitting feedback.

S&B Pharma, Inc. has applied to the Drug Enforcement Administration (DEA) to be registered as an importer of certain controlled substances. The company intends to import intermediate forms of Tapentadol for manufacturing purposes and ANPP to produce other controlled substances, but they will not import finished products for commercial sale. Interested parties, such as registered manufacturers, can submit comments, objections, or request a hearing regarding this application by March 18, 2021.

The Drug Enforcement Administration (DEA) announced that Mountain Trading LLC has applied to be registered as a bulk manufacturer of marihuana, a controlled substance listed under schedule I. The DEA will evaluate this application, along with others, based on the criteria set out in relevant laws and regulations. Current bulk manufacturers and other applicants can submit comments or objections to this application until April 19, 2021. If registered, the company will produce active pharmaceutical ingredients for research purposes only and must comply with established safeguards against drug diversion.

The Drug Enforcement Administration (DEA) has announced that Natural Fulfillment LLC has applied to become a registered manufacturer to produce controlled substances in bulk, particularly marihuana, for scientific and medical research. Interested parties, including other registered manufacturers and applicants, have until March 15, 2021, to submit their comments or raise objections to this application. If approved, Natural Fulfillment LLC will be authorized to produce bulk active pharmaceutical ingredients (APIs) for distribution to DEA-registered researchers, in compliance with all relevant laws and regulations to prevent misuse.

The Drug Enforcement Administration (DEA) has revoked the DEA Certificate of Registration for Dr. Shiva Akula after finding that he is not authorized to handle controlled substances in Louisiana, as his medical license is suspended and his controlled substances license is lapsed. The decision follows a Motion for Summary Disposition by the DEA, which Dr. Akula did not respond to, and a recommendation from the Administrative Law Judge supporting the revocation. Consequently, Dr. Akula is also denied any pending applications to renew or modify the registration. This decision was signed by DEA Administrator Anne Milgram and will take effect on January 29, 2025.

Sigma Aldrich Co. LLC. has applied to the Drug Enforcement Administration (DEA) to become an importer of certain controlled substances, specifically for drug testing and analysis in research facilities. The application was submitted on January 15, 2021. Public comments or objections regarding this proposed registration are invited until March 18, 2021. The company plans to import synthetic Tetrahydrocannabinols; however, their registration does not authorize them to import finished drug products for commercial sale.

The Department of Justice's Drug Enforcement Administration (DEA) is seeking public comments on its information collection proposal related to electronic prescriptions for controlled substances. This collection is critical for verifying practitioners' identities and managing their access to prescription systems securely. Affected groups include businesses, non-profits, and government entities, required to respond mandatorily. The DEA estimates that the total annual time burden for respondents will be 107,733 hours, with no additional cost burdens. Comments on the proposal will be accepted until March 3, 2025.

Invizyne Technologies, Inc. has applied to the Drug Enforcement Administration (DEA) to become a registered bulk manufacturer of certain controlled substances, including synthetic Tetrahydrocannabinols. Stakeholders, such as current manufacturers and applicants, can submit comments or objections electronically through the Federal eRulemaking Portal by March 24, 2025, and may also request a hearing by the same date. The DEA has provided detailed instructions for submitting comments online and has assured that comments will receive a Comment Tracking Number upon successful submission.